Chemical & Engineering News, a weekly publication of American Chemical Association (ACS) published an article titled A BACTERIAL BATTLE on June 14, 2014. “Bacteria are outsmarting us,” the author stated. “Every day they grow better at evading the drugs we deploy against them, and new molecular weapons are getting harder to find. The gap between our arsenal and bacteria’s ability to resist it is now so wide that the World Health Organization issued a report earlier this year warning that we could soon find ourselves in a post-antibiotic era.”

“It sounds apocalyptic, but infectious disease specialists and drug developers have been sounding the alarm on antibiotic resistance for years. Already, doctors are helpless against infections such as drug-resistant gonorrhea. Medical professionals are trying to prevent infections and use the remaining effective antibiotics more wisely, but new treatments are needed to replace the drugs that bacterial resistance has rendered useless. Few new antibiotic drugs have been approved in the past decade, and experts say not enough new ones are being developed to counter resistance. From 2000 to 2014, just nine new antibiotics gained Food & Drug Administration approval; by comparison, 20 were approved from 1990 to 1999, and 43 were launched in the decade before that. “We know that the current pipeline is not sufficient,” says Helen Boucher , an infectious diseases specialist at Tufts University School of Medicine. “We need more antibiotics for gram-negative bacteria, and we also need better choices for some of our patients for gram-positive infections.”

The article provides a summary of new antibiotics that are in clinical development. “The Regulatory path to approving new antibiotics has been cleared, but work still remains to rebuild a"HEATHY DRUG PIPELINE”.

For the original article, please see: http://cen.acs.org/articles/92/i24/Bacterial-Battle.html.

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.

For more information, please visit: www.tennortherapeutics.com